Geode Capital Management
CDIO icon

Geode Capital Management’s Cardio Diagnostics CDIO Stock Holding History

Geode Capital Management’s Portfolio CDIO Stock Details CDIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57.4K Sell
26,233
-5,944
-18% -$11.2K ﹤0.01% 4215
2026
Q1 		$62.7K Buy
32,177
+17,042
+113% +$44.6K ﹤0.01% 4261
2025
Q4 		$41K Buy
15,135
+37
+0.2% +$135 ﹤0.01% 4269
2025
Q3 		$60.8K Buy
15,098
+1,733
+13% +$6.84K ﹤0.01% 4248
2025
Q2 		$48.1K Buy
13,365
+198
+2% +$1.48K ﹤0.01% 4227
2025
Q1 		$130K Buy
13,167
+1,021
+8% +$15.9K ﹤0.01% 3960
2024
Q4 		$334K Buy
12,146
+5,999
+98% +$83.2K ﹤0.01% 3726
2024
Q3 		$41.1K Buy
6,147
+329
+6% +$4.04K ﹤0.01% 4299
2024
Q2 		$96K Buy
5,818
+742
+15% +$17.5K ﹤0.01% 4151
2024
Q1 		$216K Buy
5,076
+462
+10% +$26.3K ﹤0.01% 3919
2023
Q4 		$345K Buy
4,614
+2,098
+83% +$72.6K ﹤0.01% 3742
2023
Q3 		$25.7K Hold
2,516
– – ﹤0.01% 4577
2023
Q2 		$89.8K Buy
2,516
+40
+2% +$2.26K ﹤0.01% 4369
2023
Q1 		$290K Buy
+2,476
New +$195K ﹤0.01% 3875

Other funds holding CDIO

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management's CDIO Position: Q2 2026 in Review

Geode Capital Management reduced its Cardio Diagnostics (CDIO) stake by 18% in Q2 2026, selling an estimated $11.2K and leaving 26,233 shares worth $57.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4215.

Geode Capital Management first reported a position in CDIO in Q1 2023 and has held it in 14 quarters since. The position peaked at $345K in Q4 2023. 17 funds tracked by Wall St. Rank hold CDIO as of Q2 2026.

  • Geode Capital Management held 26,233 shares of Cardio Diagnostics worth $57.4K as of Q2 2026.
  • Geode Capital Management sold 5,944 Cardio Diagnostics shares in Q2 2026, an estimated $11.2K.
  • Cardio Diagnostics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #4215 holding.
  • Geode Capital Management first reported a position in Cardio Diagnostics in Q1 2023 and has held it in 14 quarters since.
  • Geode Capital Management's Cardio Diagnostics position peaked at $345K in Q4 2023.
  • 17 funds tracked by Wall St. Rank held Cardio Diagnostics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.